http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation
-
Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend
-
Pfizer Announces Positive Top-Line Results from REFLECTIONS B537-02 Study for PF-06438179 (infliximab-Pfizer) a Potential Biosimilar to Remicade® (infliximab)
-
Pfizer's (PFE) Ibrance Receives Positive EMA CHMP Opinion for Marketing in EU
-
Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe
-
Pfizer (PFE), Merck (MRK) Announce Ertugliflozin Phase 3 Met Primary Endpoint in T2D
-
Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
-
Pfizer (PFE) Announces FDA AdCom Recommendation to Remove Boxed Warning from CHANTIX
-
FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizer’s Smoking Cessation Therapy, CHANTIX® (varenicline)
-
AnTolRx, Inc. Announces Series A Equity Funding from Pfizer, JDRF and Orion Equity Partners, LLC to Develop Targeted Nanoparticle Tolerance Therapeutics
-
AnTolRx, Inc. Announces Series A Equity Funding from Pfizer, JDRF and Orion Equity Partners, LLC to Develop Targeted Nanoparticle Tolerance Therapeutics
-
Pfizer (PFE) Receives EC Approval for XALKORI as ROS1-Positive Advanced NDCLC Treatment
-
XALKORI® (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
-
Pfizer (PFE) Enters Agreement to Acquire AstraZeneca's (AZN) Small Molecule Anti-Infective Business in ~$1.58B Deal
-
Pfizer to Acquire Small Molecule Anti-Infective Business from AstraZeneca
-
Bristol-Myers Squibb (BMY), Pfizer (PFE) Will Present New Eliquis Data at ESC Congress 2016
-
Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016
-
Pfizer to Acquire Medivation
-
Pfizer (PFE) to Acquire Medivation (MDVN) in $14B Deal
-
Pfizer To Acquire Medivation
-
Pfizer (PFE) Announces FDA Approval of TROXYCA ER for Pain Management
-
FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain
-
Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease
-
Pfizer (PFE) Acquires Bamboo Therapeutics for $150M Plus $495M Contingent
-
Pfizer Aims to Become Industry Leader in Gene Therapy with Acquisition of Bamboo Therapeutics, Inc.
-
Pfizer Announces Positive Top-Line Results from Pivotal Phase 3 Maintenance Trial of Oral XELJANZ® (Tofacitinib Citrate) in Ulcerative Colitis
-
Pfizer (PFE), Western Oncolytics Enter Immuno-Oncology Research Collaboration
-
Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel Oncolytic Virus Technology
-
Pre-Open Stock Movers 07/27: (SQNM) (LOGI) (AAPL) Higher; (GMED) (AKAM) (TWTR) Lower (more...)
-
After-Hours Stock Movers 07/26: (LOGM) (AAPL) (EW) Higher; (TWTR) (AKAM) (MTCH) Lower (more...)
-
Spark Therapeutics (ONCE), Pfizer (PFE) Offer Updated SPK-9001 Phase 1/2 Data in Hemophilia B
-
Spark Therapeutics and Pfizer Announce Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity
-
Spark Therapeutics (ONCE), Pfizer (PFE) Receive FDA Breakthrough Therapy Designation for SPK-9001 as Hemophilia B Treatment
-
Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B
-
Pfizer's (PFE) Prevenar 13 Receives WHO Prequalification for Four-Dose MDV
-
Pfizer Receives World Health Organization Prequalification for Multi-Dose Vial Presentation of Prevenar 13®
-
Pfizer (PFE) Announces Data from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment Published in JAAD
-
Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis
-
Pfizer (PFE) Prevnar 13 Granted FDA Approval for Ages 18-49
-
Pfizer Receives FDA Approval for Prevnar 13® in Adults Age 18 Through 49
-
Pfizer's (PFE) SUTENT Phase 3 Met Primary Endpoint
-
Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT® (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma
-
Pfizer (PFE), Merck (MRK) Commence Aveluma Combo Phase 3 in Ovarian Cancer
-
Merck and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer
-
Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer
-
Pfizer (PFE) Announces Two Additional Bococizumab Phase 3s Met Primary Endpoints
-
Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results
-
Pfizer (PFE) Will Make $350M Investment in New, China-Located Global Biotechnology Center
-
Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China
-
Pfizer (PFE) Completes Acquisition of Anacor (ANAC)

